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Fig. S1 Flow chart of the preparation of O-glycome ‘beam search’ array. 
  
Fig. S2 Relative binding intensities of the VP8* proteins of rotavirus P[10] and P[19] (at 25 
µg/mL), antibodies and the lectin Ulex europaeus agglutinin I in the mucin glycoprotein 
(primary beam search) array. 
  
Fig. S3 Gel filtration chromatography of the products of reductive alkaline hydrolysis from PSM.  
  
Fig. S4 High performance TLC of the large scale NGL reaction mixtures of PSM neutral-glycan 
alditol fractions d to k.  
  
Fig. S5 High performance TLC of the pooled PSM neutral O-glycome NGL reaction mixture 
fractionated on a silica cartridge.   
  
Fig. S6 Beam search array data from exploratory experiments to explore binding of the VP8* 
protein of rotavirus P[19] to arrayed neutral O-glycome NGL fractions from PSM. 
  
Fig. S7 Microarray analysis of VP8* proteins of P[10] and P[19] enteroviruses using PSM neutral 
O-glycome NGL secondary beam search array. 





Table S1. Microarray analyses of the VP8* proteins of P[10] and P[19] enteroviruses (at 25 µg/mL),  antibodies to blood group antigens 
and the lectin Ulex europaeus agglutinin I (UEA-I)  using the macromolecule  array of 30 mucin-enriched epithelial glycoproteins.  
 
Position1 Mucin2 














Enriched cystadenoma mucins 
1 Cys 350 (Trp) 3-NS 4 -5 6  -   -   -  261 46   -   2,042   -  
2 Cys 444 (Pro) -NS 216 585  -   -       117           1    1,894           3   -   -  
3 Cys 444 (Trp) -NS 1276 1967        21   -    2,215        234       298   -      455   -  
4 Cys 446 (Pro) -NS 91 134  -   -   -   -    7,952         57      199   -  
5 Cys 461 (Pro) -NS 16374 5153   -   -    1,203   -       112         15   -   -  
6 Cys 461(Trp) -NS 18393 7586  -   -    6,231   -         28         40         21   -  
7 Cys 654 (Pro) -NS - -  -   -   -          11    1,776   -         11   -  
8 Cys 705 (Pro) -NS - -        87   -   -   -    9,350         21       451   -  
9 Cys 717 (Pro) -NS - 47      116   -   -   -    9,225          20       143   -  
10 Cys 733 (Pro) -S - 5936  -   -     5,227   11,626   32,460   32,728  47,640   -  
11 Cys 745 (Pro) -NS 712 -  -   -   -       438     1,763          32         63   -  
12 Cys 754 (Pro) -NS - -  -   -   -   -     1,030   -           8   -  
13 Cys 756 (Pro) -NS 82 242   -   -   -          58     3,359          13       146   -  
14 Cys 756(Trp) -NS 2756 3102  -   -   -        715        226            9      625   -  
15 Cys 762 (Pro) -NS 3498  2109        218   -   -   -     2,207          12         14   -  
16 Cys 762(Trp) -NS 9419 5176    2,189   -          49   -          76   -         56   -  
17 Cys 765 (Pro) -NS - -         12         21   -   -        771   -         13   -  
Meconia 
18 Meconium B (Pro)-S 18543 6311  13,501    2,625     9,985          36   -          88   -  12,416  
19 Meconium Mo (Pro) 5567 3248  -           9      1,405     1,934   -        165         11   -  
20 Meconium Wo (Pro) 11469 3932       863   -     1,193        289   -        169   -   -  
21 Meconium He (Pro)-S 10014 4913    1,047   -        118            7   -   -   -  11,693  
22 Meconium Pa (Pro)-S 9953 4855    8,808       515      5,450            2   -          29   -    7,597  
Purified cystadenoma mucins 
23 B substance (Pro) -S 3040 4496       926   -     1,387         81   -            9         60   9,261  
24 Og 10% 2x (Pep) -NS 13035 4222  -   -   -            2   -   -   -   -  





26 N1 20% (Pep) -NS 17072 7781  -   -      3,479   -            2          33   -   -  
27 Tij 10% 2x (Pep)-S 9792 5434    1,812       738      7,535   11,972   23,692   18,269  22,773   -  
Other glycoproteins 
28 HCA  - - NI6 NI NI NI NI NI NI NI 
29 Porcine gastric mucin-‘S’ 16533 5612  10,256       794    52,423   15,130   26,023   40,912       236           9  
30 Bovine submaxillary mucin 3944 2665  -       311      7,168     1,963            6            3           3   -  
      
1 Position in the array  
2 Samples 1-17 and 23 were mucin enriched preparations from ovarian cystadenoma fluid samples(1); 18-22 were enriched from 
meconia by protease digestions and ethanol precipitation; Samples 24-27 were purified glycoproteins from ovarian cystadenoma 
glycoproteins(2); sample 28 was a glycoprotein extract from human lung cancer(3, 4). 
3 Trp, Pro and Pep refer to trypsin, Pronase, or pepsin enzyme treatments for solubilizing mucin-type glycoproteins. 
4S, NS refer to secretor or non-secretor status where designated in archival records. 
5-, Fluorescence signals less than 1 
6 NI means not included in the analyses.   The P[10] and P[19] VP8* proteins were analysed with Mucin array set 2 and antibodies and 






Table S2. Molecular ions and deduced monosaccharide compositions of the major components 
detected by MALDI-MS analyses and hexose contents in PSM neutral O-glycome fractions obtained 
by Bio-Gel P4 chromatography.  
 
Designations [M+Na]+ Composition Hexose 
(mg) 
 Designations [M+Na]+ Composition Hexose 
(mg) 
d1 20552 dH1H4N63 184  
 
 
h 1122 dH1H2N3 4 
 2405 dH2H4N7    1179 H2N4  
 1690 dH1H3N5 
 








































 976 H2N3  
 2112 H4N7    1017 H1N4  
      814 H1N3  
e 1325 dH1H2N4 6  919 dH1H2N2  
 1690 dH1H3N5 
 
      
 1179 H2N4   i 814 H1N3 3 
1998 dH2H4N5   1065 dH2H2N3  
 2055 dH1H4N6    1122 dH1H2N3  
 2112 H4N7    919 dH1H2N2  
   976 H2N3  
f 1179 H2N4 4   1017 H1N4  
 1325 dH1H2N4    1179 H2N4  
 1487 dH1H3N4      
 1471 dH2H2N4   j 611 H1N2 2 
 1633 dH2H3N4    773 H2N2  
 1690 dH1H3N5    814 H1N3  
 1893 dH1H3N6    757 dH1H1N2  
 1747 H3N6    554 dH1H1N1  
 2055 dH1H4N6    919 dH1H2N2  
      1065 dH2H2N3  
g 1179 H2N4 4      
 1122 dH1H2N3   k 611 H1N2 1 
 1325 dH1H2N4    554 dH1H1N1  
 1487 dH1H3N4       
 975 H2N3      Total 42 
 813 H1N3       
         
1Of the thirteen fractions designated a to m, fractions a-c, l and m contained little or no detectable 
carbohydrate and are not shown. 
2Relative intensities of molecular ions: 80-100, red; 10-70, green; less than 10, black. 
3Abbreviations: dH: Deoxyhexose ; H: Hexose; N: N-acetylhexosamine or, N-acetylhexosaminitol).  





Table S3. Molecular ions and deduced compositions from MALDI-MS analyses of the NGLs derived 
from PSM neutral O-glycome fractions.  
Designation [M-H]- Composition   [M-H]- Composition 
d 2353 H3N4-OX1   1521 H1N2-OY 
 2296 dH1H3N3-OX   1464 dH1H1N1-OY 
 1727 dH1H2N1-OX   1668 dH1H1N2-OY 
 1931 dH1H2N2-OX   1318 H1N1-OY 
 1216 H1-OX   1359 N2-OY 
 1784 H2N2-OX   1888 H2N3-OY 
 2238 dH2H3N2-OX     
 2645 dH2H3N4-OX     
 1988 H2N3-OX     
 1419 H1N1-OX     
 2092 dH1H3N2-OX     
 2134 dH1H2N3-OX     
 2604 dH2H4N3-OX     
 2662 dH1H4N4-OX     
 2719 H4N5-OX     
 2808 dH2H4N4-OX     
 2865 dH1H4N5-OX     
       
e 2353 H3N4-OX   1521 H1N2-OY 
 2296 dH1H3N3-OX   1464 dH1H1N1-OY 
 2238 dH2H3N2-OX   1668 dH1H1N2-OY 
 1931 dH1H2N2-OX   1318 H1N1-OY 
 1784 H2N2-OX   1888 H2N3-OY 
 1727 dH1H2N1-OX     
 1565 dH1H1N1-OX     
 2093 dH1H3N2-OX     
 1988 H2N3-OX     
 1216 H1-OX     
 2719 H4N5-OX     
 2500 dH1H3N4-OX     
 2604 dH2H4N3-OX     
 2645 dH2H3N4-OX     
 2661 dH1H4N4-OX     
 2808 dH2H4N4-OX     
       
f 1784 H2N2-OX   1521 H1N2-OY 
 1565 dH1H1N1-OX   1668 dH1H1N2-OY 
 1931 dH1H2N2-OX   1464 dH1H1N1-OY 
 2238 dH2H3N2-OX   1359 N2-OY 
 2296 dH1H3N3-OX   1318 H1N1-OY 
 2353 H3N4-OX   1156 N1-OY 
 2093 dH1H3N2-OX   2135 dH1H2N4-OY 
 2500 dH1H3N4-OX   2035 dH1H2N3-OY 
 1419 H1N1-OX     
 1216 H1-OX     
       
g 1784 H2N2-OX   1521 H1N2-OY 
 1565 dH1H1N1-OX   1668 dH1H1N2-OY 





 1989 H2N3-OX   1156 N1-OY 
 1054 -OX   1318 H1N1-OY 
 1216 H1-OX   1359 N2-OY 
 1419 H1N1-OX     
 2297 dH1H3N3-OX     
 2354 H3N4-OX     
 2093 dH1H3N2-OX     
 2240 dH2H3N2-OX     
       
h 1419 H1N1-OX   1521 H1N2-OY 
 1565 dH1H1N1-OX   1464 dH1H1N1-OY 
 1728 dH1H2N1-OX   1668 dH1H1N2-OY 
 1786 H2N2-OX   1229 H1N1-OY 
 1932 dH1H2N2-OX     
 1216 H1-OX     
       
i 1419 H1N1-OX   1464 dH1H1N1-OY 
 1581 H2N1-OX   1521 H1N2-OY 
 1728 dH1H2N1-OX   1318 H1N1-OY 
 1565 dH1H1N1-OX   1359 N2-OY 
 1785 H2N2-OX   1156 N1-OY 
 1622 H1N2-OX   1668 dH1H1N2-OY 
 1932 dH1H2N2-OX   1831 dH1H2N2-OY 
 2240 dH2H3N2-OX     
 2354 H3N4-OX     
 2500 dH1H3N4-OX     
 1216 H1-OX     
       
j 1419 H1N1-OX   1318 H1N1-OY 
 1565 dH1H1N1-OX   1464 dH1H1N1-OY 
 1581 H2N1-OX   1156 N1-OY 
 1728 dH1H2N1-OX   1521 H1N2-OY 
 1786 H2N2-OX   1668 dH1H1N2-OY 
 1216 H1-OX     
       
k 1419 H1N1-OX   1521 H1N2-OY 
 1565 dH1H1N1-OX   1464 dH1H1N1-OY 
 1363 dH1H1-OX   1668 dH1H1N2-OY 
 1216 H1-OX   1156 N1-OY 
 1728 dH1H2N1-OX   1318 H1N1-OY 
 1785 H2N2-OX   1888 H2N3-OY 
 1932 dH1H2N2-OX     
 2240 dH2H3N2-OX     
 
1OX: -OCH2-CH(NHAc)-CH2OH-CH2-ADHP, derived from a branch 3-linked to core GalNAcol  
OY: -OCH2-CH2-ADHP derived from a branch 6-linked to core GalNAcol.  
 
Abbreviations for monosaccharides and colour code for relative intensities of molecular ions are as in 






Table S4. Designations, lipid contents, molecular ions and deduced 
compositions (from MALDI-MS analyses) of PSM neutral O-glycome NGL 
fractions. These fractions were included in the secondary, O-glycome, array; 
and microarray analysis data of the VP8* proteins of enteroviruses P[10] and 
P[19] (at 50 µg/mL) are given. 
 




 MHP11 92 ?3        ?4  15 -6 - 
       
MHP2 3 1522 H1N2-OY  2 - - 
  1465 dH1H1N1-OY    
  1479 ?     
  1567 dH1H1N1-OX    
  1623 H1N2-OX    
       
MHP3 5 1522 H1N2-OY  3 - - 
  1668 dH1H1N2-OY     
  1624 H1N2-OX      
  1728 dH1H2N1-OX    
       
MHP4 8 1988 H2N3-OX 4 - - 
  2134 dH1H2N3-OX    
  1728 dH1H2N1-OX    
  1623 H1N2-OX     
       
MHP5 5 1668 dH1H1N2-OY 5 - - 
  1728 dH1H2N1-OX    
       
MHP6 11 1728 dH1H2N1-OX  6 - - 
  1785 H2N2-OX     
       
MHP7 24 1785 H2N2-OX  7 - - 
  1728 dH1H2N1-OX     
  1595 ?    
       
MHP8 25 1785 H2N2-OX  8 - - 
  1728 dH1H2N1-OX    
  1931 dH1H2N2-OX    
       
MHP9 11 1785 H2N2-OX  9 - - 
  1931 dH1H2N2-OX     
  2033 dH1H2N3-OY    
       
MHP10 33 1931 dH1H2N2-OX 10 - - 
  1785 H2N2-OX    
  1216 H1-OX      
  1830 dH1H2N2-OY     
  1728 dH1H2N1-OX    
       
MHP11 25 1931 dH1H2N2-OX 11 - - 
  1889 dH1H3N1-OX    
  1728 dH1H2N1-OX    





MHP12 30 1931 dH1H2N2-OX 12 - - 
       
MHP13 33 1989 H2N3-OX  13 - - 
  2135 dH1H2N3-OX     
  1931 dH1H2N2-OX     
       
MHP14 18 1989 H2N3-OX  14 - - 
  2135 dH1H2N3-OX     
  1931 dH1H2N2-OX     
  2033 dH1H2N3-OY     
       
MHP20 4 2240 dH2H3N2-OX 15 - - 
  2151 H3N3-OX    
  2297 dH1H3N3-OX    
       
MHP21 9 2151 H3N3-OX 16 - - 
  2240 dH2H3N2-OX    
  2297 dH1H3N3-OX    
  2093 dH1H3N2-OX    
  1931 dH1H2N2-OX    
       
MHP22 8 2240 dH2H3N2-OX 17 - - 
  2297 dH1H3N3-OX    
       
MHP23 8 2297 dH1H3N3-OX 18 - - 
  2354 H3N4-OX    
       
MHP24 3 2297 dH1H3N3-OX 19 - - 
  2354 H3N4-OX    
       
MHP25 0.8 2354 H3N4-OX 20 - - 
       
MHP26 0.8 2500 dH1H3N4-OX 21 - - 
  2354 H3N4-OX    
       
MHP27 0.8 2500 dH1H3N4-OX 22 - - 
       
MHP28 0.8 2646 dH2H3N4-OX 23 - - 
       
M15-19HP17 1 2090 H2N4-OY  24 - - 
  2093 dH1H3N2-OX     
       
M15-19HP2 1 1420 H1N1-OX  25 - - 
       
M15-19HP3  1522 H1N2-OY 26 - - 
       
M15-19HP4 0.8 1582 ? 27 - - 
  1668 dH1H1N2-OY     
       
M15-19HP5 1.2 1785 H2N2-OX  28 - - 
  1727 dH1H2N1-OX     
  1931 dH1H2N2-OX     
       





  2135 dH1H2N3-OX     
  1931 dH1H2N2-OX     
  1888 H2N3-OY    
       
M15-19HP7 3.8 2078 dH2H2N2-OX 30 - - 
  1931 dH1H2N2-OX    
       
M15-19HP8  1989 H2N3-OX 31 - - 
       
M15-19HP9 2.2 2280 dH2H2N3-OX  32 - - 
       
M15-19HP10 2.2 2280 dH2H2N3-OX 33 - - 
  2135 dH1H2N3-OX     
       
M15-19HP11 4 2135 dH1H2N3-OX  34 - - 
  2105 ?    
  2093 dH1H3N2-OX     
       
M15-19HP12 9 1948 H3N2-OX  35 - - 
  2135 dH1H2N3-OX     
  2034 dH1H2N3-OY     
  2093 dH1H3N2-OX     
       
M15-19HP13 8 2093 dH1H3N2-OX   36 1005 2320 
  2090 H2N4-OY     
       
M15-19HP14 8 2093 dH1H3N2-OX  37 - - 
  1948 H3N2-OX     
  2135 dH1H2N3-OX    
  2034 dH1H2N3-OY    
       
M15-19HP15 3 2093 dH1H3N2-OX  38 - - 
  2151 H3N3-OX     
       
M15-19HP16 0.8 2151 H3N3-OX  39 - - 
       
M15-19HP17 0.8 2240 dH2H3N2-OX  40 - - 
  2297 dH1H3N3-OX     
       
M15-19HP18 0.8 2354 H3N4-OX  41 - - 
  2297 dH1H3N3-OX     
       
M15-19HP19 0.8 2297 dH1H3N3-OX  42 - - 
       
M15-19HP20 0.8 ? ? 43 - - 
       
LHP1 4.5 ? ? 44 - - 
       
LHP2 3 ? ? 45 - - 
       
LHP3 3 ? ? 46 - - 
       
LHP4 1.5 ? ? 47 - - 





LHP5 1.5 2093 dH1H3N2-OX  48 - - 
  2151 H3N3-OX     
  2191 H2N4-OX     
  2296 dH1H3N3-OX     
       
LHP6 1.5 2151 H3N3-OX  49 - - 
  2296 dH1H3N3-OX     
  2337 dH1H2N4-OX    
       
LHP7 5 2240 dH2H3N2-OX 50 - - 
       
LHP8 9 2297 dH1H3N3-OX  51 - - 
       
LHP9 15 2354 H3N4-OX 52 - - 
       
LHP10 6 2500 dH1H3N4-OX  53 - 1284 
  2354 H3N4-OX     
       
LHP11 8 2500 dH1H3N4-OX  54 - - 
  2646 dH2H3N4-OX     
       
LHP12 9 2646 dH2H3N4-OX  55 897 1746 
  2458 dH1H4N3-OX    
       
LHP13 2 2458 dH1H4N3-OX 56 4599 5449 
  2662 dH1H4N4-OX    
       
LHP14 3 2605 dH2H4N3-OX 57 3175 5848 
  2662 dH1H4N4-OX    
       
LHP15 1 2662 dH1H4N4-OX 58 - 198 
  2719 H4N5-OX    
  2751 dH3H4N3-OX    
       
LHP 16 2 2719 H4N5-OX 59 - - 
  2808 dH2H4N4-OX    
  2865 dH1H4N5-OX    
       
LHP 17 2 2808 dH2H4N4-OX 60 6859 9189 
  2970 dH2H5N4-OX    
       
PSM    61 7599 7118 
 
1 Suffixes M and L refer to HPLC fractions of NGLs with middle and lower migrating 
features in HPTLC. Other abbreviations and colour codes are as defined in Tables S2 
and S3. 
2 The amount of fluorescent lipid in nanomoles. 
3 Fractions MHP1 and LHP1 to LHP4 at the solvent front contained lipid but no 
detectable carbohydrate.  
4 ? , Unspecified component. 
5 Position in the array. 
6 Fluorescence signals shown are at 5 fmol of lipid per spot; -, signal less than 1. 
7 Subfractions M15 to M19 of the ‘middle’ migration NGLs were pooled and re-






Table S5. Microarray analyses of the VP8* proteins of enteroviruses P[10] and P[19] (at 50 µg/mL), antibodies 
to blood group antigens and the lectin Ulex europaeous agglutinin I  using the PSM neutral O-glycome primary 
beam search array. 
 
Position Fractions 














1 MHP1 - 1 - - - 187 1,448 - 2 - - 
2 MHP2 - - - 13,106 4,737 14,463 11 506 - - 
3 MHP3 - - - 2,654 1,322 40,299 95 4,655 - - 
4 MHP4 - - - 3,009 2,540 29,168 1,232 1,028 - - 
5 MHP5 - - - 1,417 629 36,159 166 6,100 - - 
6 MHP6 - - 2,851 22,983 1,827 15,030 - 224 - - 
7 MHP7 - - - 10,154 1,338 9,689 - 51 - - 
8 MHP8 - - - 3,198 1,462 16,530 170 85 - - 
9 MHP9 - - - 2,310 1,918 42,141 14,104 5,554 - - 
10 MHP10 - - - 16,909 1,876 44,433 947 14,640 - - 
11 MHP11 - - 563 2,630 3,383 23,468 - 1,428 - - 
12 MHP12 - - 414 1,825 3,048 18,824 - 1,090 - - 
13 MHP13 - - - 1,175 4,134 27,147 854 1,016 - - 
14 MHP14 - - 40 1,113 5,495 24,730 563 2,770 - - 
15 MHP20 - - - 793 6,302 31,415 1,552 2,417 - - 
16 MHP21 - - - 218 2,761 22,388 2,055 539 - - 
17 MHP22 - - 66 880 6,489 24,068 - 1,399 - - 
18 MHP23 - - 149 257 4,068 14,806 - 254 - - 
19 MHP24 - - 471 13 3,720 21,063 4 759 - - 
20 MHP25 - - - - 1,299 21,285 - 904 - - 
21 MHP26 - - 90 178 3,562 37,618 92 5,964 - - 
22 MHP27 - - 915 635 5,418 36,989 216 8,667 - - 
23 MHP28 - - 689 163 2,414 28,668 - 4,517 - - 
24 M15-19 HP1 - - - - - - - - - - 
25 M15-19 HP2 - - - - 65 - - - - - 
26 M15-19 HP3 - - - 4,643 2,773 4,744 - 6 - - 
27 M15-19 HP4 - - - 2,911 1,874 17,288 - 558 - - 
28 M15-19 HP5 - - - 1,288 2,558 13,051 36 441 - - 
29 M15-19 HP6 - - - 2,231 6,302 19,396 72 1,189 - - 
30 M15-19 HP7 - - - 7,418 13,950 13,566 - 475 - - 
31 M15-19 HP8 - - 108 2,813 8,278 31,440 1,268 2,000 - - 
32 M15-19 HP9 - - - 103 3,197 18,556 - 676 - - 
33 M15-19 HP10 - - - 934 8,310 38,387 7 8,592 - - 
34 M15-19 HP11 - - 17,155 1,452 5,018 38,770 - 11,195 - - 
35 M15-19 HP12 - - 2,169 5,647 11,169 28,213 - 4,145 - - 
36 M15-19 HP13 1,005 2,320 14,767 - 1,468 16,895 1,287 200 - - 
37 M15-19 HP14 - - 825 1,425 6,293 21,266 - 1,069 - - 
38 M15-19 HP15 - - 517 350 5,363 19,195 2,889 78 - - 
39 M15-19 HP16 - - 1,411 240 4,790 27,064 2,277 325 - - 
40 M15-19 HP17 - - 1,429 399 6,086 19,821 477 250 - - 
41 M15-19 HP18 - - - - 652 3,882 - - - - 











43 M15-19 HP20 - - - - - - - - - - 
44 LHP1 - - - - 110 297 - - - - 
45 LHP2 - - - - 250 1,875 - 44 - - 
46 LHP3 - - - 869 120 580 - - - - 
47 LHP4 - - - 12 428 2,529 22 - - - 
48 LHP5 - - 2,349 732 1,857 17,473 1,260 111 - - 
49 LHP6 - - - - 468 20,522 7,298 133 - - 
50 LHP7 - - - 263 3,822 17,090 442 532 - - 
51 LHP8 - - 1,572 629 2,743 15,258 179 287 - - 
52 LHP9 - - 1,013 314 2,465 20,428 554 659 - - 
53 LHP10 - 1,284 4,788 1,589 6,200 38,178 3,789 6,229 - - 
54 LHP11 - - 1,846 687 2,688 36,040 1,623 8,053 - - 
55 LHP12 897 1,746 19,645 4,471 3,374 37,503 1,446 6,532 - - 
56 LHP13 4,599 5,449 19,320 5,434 6,258 34,728 13,216 2,727 - - 
57 LHP14 3,175 5,848 17,783 7,050 5,111 31,231 7,137 2,161 - - 
58 LHP15 - 198 5,194 2,744 3,545 27,602 4,546 1,528 - - 
59 LHP16 - - 4,468 3,101 5,967 26,629 2,538 1,847 - - 
60 LHP17 6,859 9,189 24,131 9,196 28,062 42,635 16,843 8,397 - - 





Table S6. Microarray analyses of the VP8* proteins of the P[10] and P[19] enteroviruses (at 50 µg/mL) using the secondary array designated ‘Fucase Array’. 
Four sub-fractions, Bands 1-4, isolated by semi-preparative TLC from fraction M15-19HP13 and twelve sequence-defined NGL probes constituted the array 
which was used for analyses before and after on-array treatment with α1-2 fucosidase.  
Position Probes Composition/Sequence 
Fluorescence signals (5 fmol/probe spot) 
P[10] P[19] Anti-H type 1 Anti-H type 2 Anti-LNT 
Before After Before After Before After Before After Before After 
1  Band 1 H2N4-OY  -   -   -   -  162   -           280   -   -   -  
2  Band 2 dH1H3N2-OX    13,432      1,901       12,969     2,874       34,298   -        1,213   -   -      39,543  
3  Band 3 
dH1H3N2-OX 




4  Band 4 
H3N2-OX 
           456   -            852   -         4,123   -            304   -   -            309  dH1H3N2-OX 
H3N3-OX 
5 LNFP-I Fucα-2Galβ-3GlcNAcβ-3Galβ-4Glc-DH1            519   -            907   -        13,296   -              35   -   -   -  




Fucα-2Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3Galβ-4Glcβ-Cer2  -   -   -   -   -   -      31,484             37   -   -  
8 GSC-915-3 Fucα-2Galβ-4GlcNAcβ-6Galβ-4GlcNAcβ-3Galβ-4Glc-DH  -   -   -   -   -   -      41,601             41              17   -  
9 LNT Galβ-3GlcNAcβ-3Galβ-4Glc-DH  -   -   -   -   -   -   -             45   -   -  
10 LNnT Galβ-4GlcNAcβ-3Galβ-4Glc-DH  -   -   -   -   -   -   -   -   -   -  
11 pLNnH Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3Galβ-4Glc-DH  -   -   -   -   -   -   -   -   -   -  
12 GSC-915-4 Galβ-4GlcNAcβ-6Galβ-4GlcNAcβ-3Galβ-4Glc-DH  -   -   -   -   -   -            224   -   -   -  
13 pLNH Galβ-3GlcNAcβ-3Galβ-4GlcNAcβ-3Galβ-4Glc-DH         1,046       1,082        1,800     2,310   -   -   -   -      27,501      33,651  
14 pLNH-b Galβ-3GlcNAcβ-3Galβ-3GlcNAcβ-3Galβ-4Glc-DH         1,571       1,525                 3   -   -   -   -   -   -   -  
15 LNDFH-I 
Fucα-2Galβ-3GlcNAcβ-3Galβ-4Glc-DH 
            │ 
       Fucα-4 
 -   -   -   -   -   -   -   -   -   -  
16 LNFP-II 
Galβ-3GlcNAcβ-3Galβ-4Glc-DH 
      │ 
 Fucα-4 
 -   -   -   -   -   -   -   -   -   -  
1 DH, designates NGLs prepared from reducing oligosaccharides by reductive amination with the amino lipid, 1,2-dihexadecyl-sn-glycero-3-
phosphoethanolamine;  
2 Cer, natural glycolipid with various ceramide moieties.  
*Asterisk  indicates the  the presecne of a minor component with an additional fucose residue detected by MALDI-MS; most likely these are part of a 






Table S7. Microarray analyses of the enterovirus P[10] and P[19] VP8* proteins (at 50 µg/mL) using the array of  sequence-defined probes 
designated  F77/Ii array . 
   
fluorescence signals  
(5 fmol/probe spot) 
Position Probes Structure  P[10]   P[19]  
1 Orsay-1-AO Galβ-4GlcNAcβ-6Gal-AO1  -2   -  
2 Orsay-2-AO Galβ-4GlcNAcβ-3Gal-AO  -   -  
3 Orsay-3-AO Galβ-3GlcNAcβ-6Gal-AO  -    1,384  
4 Orsay-4-AO Galβ-3GlcNAcβ-3Gal-AO       55   -  
5 LNT Galβ-3GlcNAcβ-3Galβ-4Glc-DH1  -   -  
6 LNnT Galβ-4GlcNAcβ-3Galβ-4Glc-DH  -   -  
7 LSTa NeuAcα-3Galβ-3GlcNAcβ-3Galβ-4Glc-DH  -   -  
8 LSTc NeuAcα-6Galβ-4GlcNAcβ-3Galβ-4Glc-DH       36   -  
9 LSTd NeuAcα-3Galβ-4GlcNAcβ-3Galβ-4Glc-DH  -   -  
10 pLNH Galβ-3GlcNAcβ-3Galβ-4GlcNAcβ-3Galβ-4Glc-DH  1,243    1,798  
11 pLNnH Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3Galβ-4Glc-DH  -   -  
12 LNnO Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3Galβ-4Glc-DH  -   -  
13 O1-AO 
GlcNAcβ-6 
        │ 
        Gal-AO 
        │ 
GlcNAcβ-3 
    359  28,382  
14 Orsay-5-AO 
      GlcNAcβ-6 
              │ 
              Gal-AO 
              │ 
Galβ-3GlcNAcβ-3 
      68  13,668  
15 Orsay-6-AO 
Galβ-4GlcNAcβ-6 
              │ 
              Gal-AO 
              │ 
Galβ-3GlcNAcβ-3 







              │ 
              Gal-AO 
              │ 
Galβ-4GlcNAcβ-3 
 -   -  
17 LNH 
Galβ-4GlcNAcβ-6 
              │ 
              Galβ-4Glc-DH 
              │ 
Galβ-3GlcNAcβ-3 
 -         65  
18 LNnH 
Galβ-4GlcNAcβ-6 
              │ 
              Galβ-4Glc-DH 
              │ 
Galβ-4GlcNAcβ-3 
 -         92  
19 MSLNH 
NeuAcα-6Galβ-4GlcNAcβ-6 
                      │ 
                      Galβ-4Glc-DH 
                      │ 
        Galβ-3GlcNAcβ-3 
 -   -  
20 MSLNnH-I 
        Galβ-4GlcNAcβ-6 
                      │ 
                      Galβ-4Glc-DH 
                      │ 
NeuAcα-6Galβ-3GlcNAcβ-3 
 -   -  
21 DSLNnH 
NeuAcα-6Galβ-4GlcNAcβ-6 
                      │ 
                      Galβ-4Glc-DH 
                      │ 
NeuAcα-6Galβ-4GlcNAcβ-3 
 -   -  
22 iLNO 
Galβ-3GlcNAcβ-3Galβ-4GlcNAcβ-6 
                             │ 
                             Galβ-4Glc-DH 
                             │ 
               Galβ-3GlcNAcβ-3 







              │ 
              Galβ-4GlcNAcβ-6 
              │             │ 
Galβ-3GlcNAcβ-3             Galβ-4Glc-DH 
                            │ 
              Galβ-3GlcNAcβ-3 
 -   -  
24 Nonaosylceramide 
              GlcNAcβ-6 
                      │ 
GlcNAcβ-6             Galβ-4GlcNAcβ-3Galβ-4Glcβ-Cer 
        │             │ 
        Galβ-4GlcNAcβ-3 
        │ 
GlcNAcβ-3 
      59       205  
25 I-octaosylceramide 
Galβ-4GlcNAcβ-6 
              │ 
              Galβ-4GlcNAcβ-3Galβ-4Glcβ-Cer 
              │ 
Galβ-4GlcNAcβ-3 
 -   -  
26 I-dodecaosylceramide 
              Galβ-4GlcNAcβ-6 
                            │ 
Galβ-4GlcNAcβ-6             Galβ-4GlcNAcβ-3Galβ-4Glcβ-Cer 
              │             │ 
              Galβ-4GlcNAcβ-3 
              │ 
Galβ-4GlcNAcβ-3 





                    │ 
                    Galβ-4GlcNAcβ-3Galβ-4Glcβ-Cer 
                    │ 
Galα-3Galβ-4GlcNAcβ-3 




              Galα-3Galβ-4GlcNAcβ-6 
                                  │ 
Galα-3Galβ-4GlcNAcβ-6             Galβ-4GlcNAcβ-3Galβ-4Glcβ-Cer 
                    │             │ 
                    Galβ-4GlcNAcβ-3 
                    │ 
Galα-3Galβ-4GlcNAcβ-3 







      │ 
 Fucα-4 
 -   -  
30 Leb-hexaosylceramide 
Fucα-2Galβ-3GlcNAcβ-3Galβ-4Glcβ-Cer 
            │ 
       Fucα-4 
      75   -  
31 LNFP-III 
Galβ-4GlcNAcβ-3Galβ-4Glc-DH 
      │ 
 Fucα-3 
 -       147  
32 LNnDFH-I 
Fucα-2Galβ-4GlcNAcβ-3Galβ-4Glc-DH 
            │ 
       Fucα-3 
 -   -  
33 MFLNH-I 
      Galβ-4GlcNAcβ-6  
                    │  
                    Galβ-4Glc-DH 
                    │  
Fucα-2Galβ-3GlcNAcβ-3 
        5   -  
34 DFLNH(b) 
Galβ-4GlcNAcβ-6 
      │       │ 
 Fucα-3       Galβ-4Glc-DH 
              │ 
Galβ-3GlcNAcβ-3 
      │ 
 Fucα-4 
    111   -  
35 TFLNH 
      Galβ-4GlcNAcβ-6  
            │       │  
       Fucα-3       Galβ-4Glc-DH 
                    │  
Fucα-2Galβ-3GlcNAcβ-3  
            │  
       Fucα-4 
 -         93  
36 DFLNnH 
Galβ-4GlcNAcβ-6 
      │       │ 
 Fucα-3       Galβ-4Glc-DH 
              │ 
Galβ-4GlcNAcβ-3 
      │ 
 Fucα-3 






  Fucα-2Galβ-4GlcNAcβ-6  
               │      │ 
          Fucα-3      Galβ-4Glc-AO 
                      │  
NeuAcα-6Galβ-4GlcNAcβ-3 
 -   -  
38 DFiLNO 
Galβ-3GlcNAcβ-3Galβ-4GlcNAcβ-6 
                     │       │ 
                Fucα-3       Galβ-4Glc-DH 
                             │ 
         Fucα-2Galβ-3GlcNAcβ-3 
 1,768    4,585  
39 TFiLNO(1-2,2,3) 
Fucα-2Galβ-3GlcNAcβ-3Galβ-4GlcNAcβ-6 
                           │       │ 
                      Fucα-3       Galβ-4Glc-DH 
                                   │ 
               Fucα-2Galβ-3GlcNAcβ-3 
 9,945  18,663  
40 LNFP-I Fucα-2Galβ-3GlcNAcβ-3Galβ-4Glc-DH     668    1,628  
41 LNnFP-I Fucα-2Galβ-4GlcNAcβ-3Galβ-4Glc-DH  -   -  
42 H2 (with H2+Fuc)* Fucα-2Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3Galβ-4Glcβ-Cer  -   -  
43 H3 (with H3-Fuc)* 
Fucα-2Galβ-4GlcNAcβ-6  
                    │  
                    Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                    │  
Fucα-2Galβ-4GlcNAcβ-3 
 -   -  
44 A-Hexa-T1 
GalNAcα-3Galβ-3GlcNAcβ-3Galβ-4Glc-DH 
         │ 
    Fucα-2 
    713    2,308  
45 A-Hexa-T2 
GalNAcα-3Galβ-4GlcNAcβ-3Galβ-4Glc-DH 
         │ 
    Fucα-2 
 -   -  
46 A-Hepta 
          Fucα-4 
               │ 
GalNAcα-3Galβ-3GlcNAcβ-3Galβ-4Glc-DH 
         │ 
    Fucα-2 
 -    3,636  
47 Ab (with Ab+Fuc)* 
GalNAcα-3Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3Galβ-4Glcβ-Cer 
         │ 
    Fucα-2 





48 Ad (with Ad+Fuc)* 
               GalNAcα-3Galβ-4GlcNAcβ-6 
                        │             │ 
                   Fucα-2             Galβ-4GlcNAcβ-3Galβ-4Glcβ-Cer 
                                      │ 
GalNAcα-3Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3 
         │   
    Fucα-2 
 -   -  
49 B-Hexa-T1 
Galα-3Galβ-3GlcNAcβ-3Galβ-4Glc-DH 
      │ 
 Fucα-2 
    739    1,762  
50 B-Hexa-T2 
Galα-3Galβ-4GlcNAcβ-3Galβ-4Glc-DH 
      │ 
 Fucα-2 
 -   -  
51 B-penta-AO 
Galα-3Galβ-4Glc-AO 
      │     │ 
 Fucα-2     │ 
       Fucα-3 





      │             │ 
 Fucα-2             Galβ-4GlcNAcβ-3Galβ-4Glcβ-Cer 
                    │ 
Galα-3Galβ-4GlcNAcβ-3 
      │ 
 Fucα-2 




               Galα-3Galβ-4GlcNAcβ-6 
                     │             │ 
                Fucα-2             Galβ-4GlcNAcβ-3Galβ-4Glcβ-Cer 
                                   │ 
Galα-3Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3 
      │ 
 Fucα-2 
 -   -  
54 PSM-F1H2HN3-OY 
Fucα-2Galβ-4GlcNAcβ-6  
                    │  
                    Galβ-4GlcNAcβ-OY   
                    │  
            GlcNAcβ-3 





55 PIII (proposed) 
Fucα-2Galβ-3GlcNAcβ-6  
                    │  
                    Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                    │  
Fucα-2Galβ-3GlcNAcβ-3  
        
   
                  
Fucα-2Galβ-4GlcNAcβ-6  
                    │  
                    Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                    │  
      Galβ-3GlcNAcβ-3  
 
Fucα-2Galβ-4GlcNAcβ-6  
             │      │  
        Fucα-3      Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                    │  
Fucα-2Galβ-3GlcNAcβ-3 
 -   -  
56 
PIII de Fuc (according 
to proposed structures) 
      Galβ-3GlcNAcβ-6  
                    │  
                    Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                    │  
      Galβ-3GlcNAcβ-3  
 
      Galβ-4GlcNAcβ-6  
                    │  
                    Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                    │  
      Galβ-3GlcNAcβ-3 
 
      Galβ-4GlcNAcβ-6  
             │      │  
        Fucα-3      Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                    │  
      Galβ-3GlcNAcβ-3 







                    │  
                    Galβ-4GlcNAcβ-3Galβ-4Glc-DH 
                    │  
      Galβ-4GlcNAcβ-3 
 -       153  
58 GSC-915-2 
Fucα-2Galβ-4GlcNAcβ-6  
                    │  
                    Galβ-4GlcNAcβ-3Galβ-4Glc-DH 
                    │  
            GlcNAcβ-3 
 -   -  
59 GSC-915-3 Fucα-2Galβ-4GlcNAcβ-6Galβ-4GlcNAcβ-3Galβ-4Glc-DH  -           3  
60 GSC-915-4 Galβ-4GlcNAcβ-6Galβ-4GlcNAcβ-3Galβ-4Glc-DH  -         15  
 
1 The oligosaccharide probes are all lipid-linked, neoglycolipids (NGLs) or glycosylceramides and are from the collection assembled 
in the course of research in Glycosciences Laboratory. NGLs designated DH are prepared from reducing oligosaccharides by reductive 
amination with the amino lipid, 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine (DHPE); AO-NGLs were prepared from reducing 
oligosaccharides by oxime ligation with an aminooxy (AO) functionalized DHPE(6); Cer, natural glycolipids with various ceramide 
moieties. 
2 Fluorescence signals less than 1 
*Asterisks  indicate glycolipid preparations that contain a minor component with an additional fucose residue detected by MALDI-






Table S8. Microarray analyses of. P[10] and P[19] VP8* proteins  at 100 µg/mL on an array set of 7 
gluco-oligosaccharide NGLs and LNFP1 and LNnFP1 NGLs as controls; data are at 5 fmol/spot .  
 
1 DH-NGLs were prepared from reducing oligosaccharides by reductive amination with the amino 
lipid, 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine (DHPE); AO-NGLs were prepared from 
reducing oligosaccharides by oxime ligation with an aminooxy (AO) functionalized DHPE(6). 
2 Fluorescence intensities with probes printed at 5 fmol per spot. 
3 - Indicates fluorescence intensity less than 1. 
*Asterisks indicate the major components when multiple components are present. 
  
  




1 LNFPI Fucα-2Galβ-3GlcNAcβ-3Galβ-4Glc-DH 1,053 3,188 
2 LNnFPI Fucα-2Galβ-4GlcNAcβ-3Galβ-4Glc-DH -3 - 
3 Lam-4-AO Glcβ-3Glcβ-3Glcβ-3Glc-AO - 1,061 
4 Lam-6-AO* Glcβ-3Glcβ-3Glcβ-3Glcβ-3Glcβ-3Glc-AO - 2,812 
5 Curd-8-AO* Glcβ-3Glcβ-3Glcβ-3Glcβ-3Glcβ-3Glcβ-3Glcβ-3Glc-AO - 3,397 
6 Pust-4-AO Glcβ-6Glcβ-6Glcβ-6Glc-AO - 3,781 
7 Pust-6-AO Glcβ-6Glcβ-6Glcβ-6Glcβ-6Glcβ-6Glc-AO - 2,502 
8 Pust-8-AO* Glcβ-6Glcβ-6Glcβ-6Glcβ-6Glcβ-6Glcβ-6Glcβ-6Glc-AO - 1,075 
























Fig. S1. Flow chart of steps in the O-glycome ‘beam search’ approach highlighting the three 
microarrays (yellow) that led to the identification of ligand positive components (green), and the  
pinpointing and elucidation of an O-glycan ligand for the VP8* proteins of rotaviruses P[10] and 
P[19]. Microarray analyses of the VP8* proteins of rotaviruses P[10] and P[19] on a primary 
microarray consisting of 30 mucin-enriched glycoproteins enabled the selection of porcine stomach 
mucin (PSM) as the ligand-bearing mucin from which to generate NGLs of the released O-glycan 
alditols for the secondary and tertiary arrays of NGLs. The ligand positive mucin and derived ligand 









Fig. S2. Relative binding intensities of the VP8* proteins of rotavirus P[10] and P[19] (at 25 µg/mL), 
antibodies and the lectin Ulex europaeus agglutinin I in the mucin glycoprotein (primary beam 
search) array. The P[10] and P[19] VP8* proteins were analysed with Mucin array set 2 and 













Fig. S3.| Gel filtration chromatography of the products of reductive alkaline hydrolysis from PSM. 
The Bio-Gel P4 column (1.6 × 90 cm) was eluted with water. V0: void volume; Vt: total volume; 
numbers 7-12 at the top of the figure indicate positions of glucose units (degrees of polymerization) in 














Fig. S4.| High performance TLC of the large scale NGL reaction mixtures of PSM neutral-glycan 













Fig. S5. High performance TLC of the pooled PSM neutral O-glycome NGL fractions of the reaction 
mixture eluted as nine fractions (4 ml each) from a short silica column; 1 µL of each were applied. 
The solvent was CHCl3/MeOH/H2O 60:35:8.  Fractions with middle and lower migration patterns 











Fig. S6. Beam search array data from exploratory experiments to explore binding of the VP8* protein 
of rotavirus P[19] to arrayed neutral O-glycome NGL fractions from PSM:  (a) high performance 
TLC of the pooled reaction mixture of NGLs derived from ~1mg  neutral O-glycan alditols eluted as 
seven fractions from a silica column. The solvent was CHCl3/MeOH/H2O 60:35:8. (b) and 
(c),Fractions with middle and lower migration patterns, respectively, were pooled as indicated and re-
fractionated by HPLC. The HPLC fractions were used for generating a secondary beam search array 
similarly to the large scale experiments. The horizontal bars give relative intensities of binding 
elicited by the VP8* protein of rotavirus P[19] analysed at 50 µg/mL: 100% is for the highest signal 
in the array. These data are from experiments separate from those in the large scale experiment shown 
in Fig. 2. The experimental data for the small scale experiments show reproducibly of the methods 











Fig. S7.| Microarray analysis of VP8* proteins of P[10] and P[19] enteroviruses using PSM neutral O-
glycome NGL secondary beam search array. The results are the means of fluorescence intensities of 
duplicate spots printed at 5 fmol with error bars representing half of the difference between the two 





Appendix: Glycan Microarray Document  
 
Based on MIRAGE Glycan Microarray Guidelines - Beilstein-Institut 
Glycobiology. 2016 Nov 22. [Epub ahead of print] PMID: 27993942 
 Classification  
 
1. Sample: Glycan Binding Sample 
Description of Sample 
Recombinant rotavirus VP8* proteins expressed as glutathione S-
transferase (GST)-tagged proteins as described (Liu et al. J Virol 2016).  
These and the antibodies and lectins are described in Material and 
Methods. 
Sample  modifications  no 
Assay protocol Described in Material; and Methods 
2. Glycan Library 
Glycan description for 
defined glycans  
Sequence defined glycan probes are described in Material and Methods 
and the probe names and structures are in Tables S6, 7 and 8. These 
were from the collection assembled in the course of research in the 
Glycosciences Laboratory 
(https://glycosciences.med.ic.ac.uk/glycanLibraryList.html). 
Structure determination (by immuno-sequencing) of the hexasaccharide 
ligand for the VP8* protein of the two viruses are in Results section.  
Glycan description for 
undefined glycans  
The macromolecule y array of the beam search was of mucin-type 
glycoproteins; from among these, the ligand-positive porcine stomach 
mucin (PSM) was selected for generating the primary NDL array. 
The neutral (non-acidic) O-glycans reductively released from PSM and 
fractionated by size were converted into fluorescent neoglycolipids 
(NGLs) by reductive amination following mild periodate oxidation. 
Sixty HPLC fractions of these NGLs were included in the PSM neutral 
O-glycome (secondary) array. Their designations, lipid contents, 
molecular ions and deduced compositions (from MALDI-MS analyses) 
are in Table S4.  
Four sub-fractions, Bands 1-4, isolated by semi-preparative TLC from 
fraction M15-19HP13 were included in the secondary array designated 
‘Fucase Array’ (Table S6). Their molecular ions and deduced 
monosaccharide compositions are in Figure 4b.  
Glycan modifications  
Sequence defined glycan probes: Unless otherwise specified the NGLs 
were prepared from reducing oligosaccharides by reductive amination 
with the amino lipid, 1,2-dihexadecyl-sn-glycero-3-
phosphoethanolamine [(DHPE) (Chai et al., Methods Enzymol. 2003)]; 
AO, NGLs prepared from reducing oligosaccharides by oxime ligation 






For full description of the lipid moieties of the glycan probes, please 
see https://glycosciences.med.ic.ac.uk/docs/lipids.pdf. 
The preparation of fluorescent NGLs are described in Material and 
Methods. 
1. 3. Printing Surface; e.g., Microarray Slide 
Description of surface Nitrocellulose-coated glass microarray slides.  
Manufacturer 16-pad Slides from Sartorius Stedim, Goettingen, Germany 
Custom preparation of 
surface  Not relevant.  
Non-covalent 
Immobilization  
The lipid-linked glycan probes were formulated as liposomes by 
adding carrier lipids, phosphatidylcholine and cholesterol (Liu et al., 
Methods Mol. Biol. 2012) for robotically arraying and non-covalent 
immobilization on nitrocellulose-coated glass slides. Glycoproteins 
were arrayed in water 
4. Arrayer (Printer) 
Description of Arrayer Noncontact arrayer, Nano-Plotter (Gesim, Germany) 
Dispensing mechanism Non-contact liquid delivery with four dispensing tips.  
Glycan deposition 
Approximate 0.33 nl was printed for each spot.  
Each glycan probe was printed at two levels (2 and 5 fmol per spot) in 
duplicate. Each glycoprotein was printed at 30 and 170 pg hexose per 
spot 
Printing conditions The printing solutions are detailed  in Online Methods   
2. 5. Glycan Microarray with “Map” 
Array layout 
Each array slide contained 16-pad subarrays of glycan probes printed at 
two levels in duplicate (four spots for one probe in a row) as detailed in 
Material and Methods. 
Glycan identification and 
quality control 
Antibodies and plant lectins variously used to identify glycan 
sequences in the macromolecule array and in the primary and 
secondary NGL arrays are described in Material and Methods and the 
binding data are in Tables S1, 5 and 6. 
3. 6. Detector and Data Processing 
Scanning hardware 
ProScanArray microarray scanner (PerkinElmer LAS, Beaconsfield, 
UK) or GenePix 4300A (Molecular Devices, Sunnyvale, USA). 
Scanner settings 
Scanning resolution: 10 m / pixel (this resolution is adequate for the 
sizes of sample spots) 
Laser channel: Red (scan wavelength 633 nm) 





Scan power:  ranged from 30 to 100% to avoid saturation of binding 
signals  
Image analysis software 
ScanArray Express software (PerkinElmer) or GenePix® Pro 7 
Microarray Analysis software (Molecular Devices) 
Data processing 
The gpr file was entered into an in-house microarray database using 
software (designed by Dr Mark Stoll, http://www.beilstein-
institut.de/en/publications/proceedings/glyco-2009) for data processing. 
No particular normalization method or statistical analysis was used.  
7. Glycan Microarray Data Presentation 
Data presentation 
The microarray binding results are in Fig 2, 3 and 4, Table 1 and in 
Tables S1, 4, 5, 6, 7 and 8, and Figs 2, 6, and 7 The tables include the 
list of probes in the arrays, binding intensities shown are at 170 pg or 5 
fmol per spot and errors (difference of signal intensities of duplicate 
spots of each glycan probe).  
4. 8. Interpretation and Conclusion from Microarray Data 
Data interpretation  No software or algorithms were used to interpret processed data. 
Conclusions  
1. The beam search arrays: The ligand-positive component investigated 
in detail is a minor component in the O-glycome of the porcine stomach 
mucin investigated, not previously rerported in PSM. It is assigned as a 
hexasaccharide with the type 1-terminating blood group H and an 
internal type 2 sequence, having been derived from a 3-linked branch at 
core GalNAcol:    
Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAcβ1-Galβ-3OX 
2. The sequence-defined arrays: corroborated the involvement of  type 
1-terminating blood group H in the ligand as in lacto N-fucopentaose 1 
(LNF-P1)  
Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc 
The lower intensity of binding to LNFP-1 indiated that the backbone 
beyond tetrasaccharde is additionally recognized. 
3. The complementarity of the sequence-defined arrays with the beam 
serch is highlighted with repect to revealing other natural glycan 
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